Wilex AG Share Price Deutsche Boerse AG
Equities
DE0006614720
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
|
07-11 | Heidelberg Pharma AG Reports Earnings Results for the Half Year Ended May 31, 2024 | CI |
04-25 | Heidelberg Pharma AG Reports Earnings Results for the First Quarter Ended February 29, 2024 | CI |
Sales 2024 * | 11.5M 12.59M 965M | Sales 2025 * | 15M 16.42M 1.26B | Capitalization | 121M 132M 10.13B |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 10.5 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 8.05 x |
P/E ratio 2024 * |
-8.63
x | P/E ratio 2025 * |
-19.9
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 19.37% |
Latest transcript on Wilex AG
Managers | Title | Age | Since |
---|---|---|---|
Andreas Pahl
CEO | Chief Executive Officer | - | 31/12/11 |
Walter Miller
DFI | Director of Finance/CFO | - | 30/04/23 |
András Strassz
CTO | Chief Tech/Sci/R&D Officer | - | 28/02/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 61 | 28/04/05 | |
Georg F. Baur
BRD | Director/Board Member | 74 | 13/12/00 |
Birgit Kudlek
BRD | Director/Board Member | 57 | 24/05/12 |
1st Jan change | Capi. | |
---|---|---|
+20.17% | 126B | |
+24.67% | 118B | |
+23.64% | 27.87B | |
-17.74% | 20.95B | |
-15.68% | 16.92B | |
-15.21% | 16.18B | |
+11.91% | 14.84B | |
-47.10% | 14.79B | |
+54.50% | 14.08B |